biosplice therapeutics news

Feb 2021 - Present11 months. Pipeline | Biosplice Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Prior to Biosplice, he was the Co-Founder, Portfolio Manager and a Partner of Greywolf Capital Management LP, a New York-based investment fund managing capital in different strategies. Biosplice Therapeutics has designed an unprecedented compendium of new chemical entities which selectively bind to specific members of the CLK/DYRK family and feature drug-like properties amenable to local or systemic administration and CNS exposure. This trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in multiple combination cohortsSAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a . Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. News & Events. The Present, Progress, and Potential of CDK4/6 Inhibitors ... Biosplice Therapeutics, Inc. - Biocom California SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Connect to CRM . What We Do Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Management. The platform has been shown to have long-lasting, tumor specific, immune response in treated animals. Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of a post-hoc analysis of its successful Phase 2b knee osteoarthritis clinical trial in Rheumatology and Therapy. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Haisco Pharmaceutical Group Co., Ltd. ("Haisco"), a pharmaceutical company based in the People's Republic of China ("China"), announced the execution . Biosplice - Overview, News & Competitors | ZoomInfo.com Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference NASDAQ Market News September 13, 2021 NASDAQ SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for. Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. Connect to CRM . Biosplice Therapeutics - aMoon Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. 10 Aug 2021 Biomarkers information updated. No Comments. Samumed is a leader in medical research and development for tissue-level regeneration. BNZ-2 is ready for a phase 1 clinical trial. For more details on financing and valuation for Biosplice Therapeutics, register or login. NEWSROOM. It was founded in 2008 by Osman Kibar. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for. Biotech Veterans Troy Cox, Susannah Gray and Karen ... Linda Scheer, MD - Associate Director, Medical Affairs ... Biosplice Therapeutics . this trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (sm08502) in multiple combination cohortssan diego, nov. 17, 2021 (globe newswire) -- biosplice. Dave Johnson Joins Biosplice Therapeutics Board of Directors Kevin Kwei - Senior Director, Biomarker Sciences ... Sep 15. New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice's clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based . SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase . Biosplice Therapeutics Closes $120 Million in Equity ... With our platform's origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.. Sep 2016 - Present4 years 8 months. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office . See subscription options. Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a Phase 1b, open-label, multi-center, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for. NASDAQ Oncology Market News Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform by NASDAQ Market News April 15, 2021 Save . SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics. San Diego, California, United States. SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice&CloseCurlyDoubleQuote;), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. October 14, 2021. Upgrade your daily dose of biopharma and medtech news. BNZ-2 is a multi-cytokine inhibitor of IL-15 and IL-21. Biosplice Therapeutics is in Phase . Choose the right Crunchbase solution for you . Cevdet Samikoglu Chief Executive Officer. These two cytokines are implicated in a number of diseases such as IBD, Celiac Disease, Type I diabetes, NASH. Biosplice is a biopharmaceutical company developing first-in-class, small-molecule therapeutics based on pioneering science of RNA alternative splicing. Biosplice Therapeutics . SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK . LEARN MORE. This week began with four biopharma companies announcing intentions to become publicly traded companies and it's ending with three companies making their debut on the Nasdaq. SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for . SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Recent News & Activity. . Stem cell therapies, anti-cancer viruses, gene therapy, senolytics, and whatever is coming next. Biosplice Therapeutics preserves its unique culture by building not only a management team but also an employee base that shares the same vision and values. Lead development and implementation of pricing and reimbursement strategy . SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Haisco Pharmaceutical Group Co., Ltd. ("Haisco"), a pharmaceutical company based in the People's Republic of China ("China"), announced the execution . "Mr. Johnson's vast experience ushering drugs . "We are honored to have this caliber of experience and leadership join our new board at Biosplice," said . SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. Mr. Samikoglu is a public and private investor, entrepreneur and a former investment banker. Dec. 9, 2021. Jul 22. This trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in multiple combination cohorts. Biosplice Therapeutics, Inc. April 20, 2021 GMT SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. The company's scientific platform is based on biological discoveries that govern tissue specialization and enable elimination of harmful proteins using these small molecules. This trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in multiple combination cohorts. Summary Financials People Technology Signals & News. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. This morning, two of those companies, Ikena Oncology and Design Therapeutics, join Edgewise Therapeutics by trading on the exchange. We operate in a fully-integrated, no-silo team structure and share accountability across the company. Organization. Samumed's products in development target novel components . Kevin Kwei Senior Director, Biomarker Sciences at Biosplice Therapeutics San Francisco Bay Area 500+ connections Why the sudden rebrand? Los Angeles, USA, May 25, 2021 (News) — New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsight Approximately 80+ key companies are developing Osteoarthritis Drugs.The companies with the Osteoarthritis drug candidates in the most advanced stage include Ampio Pharmaceuticals, Techfields Pharma, Biosplice Therapeutics, Taiwan Liposome Company and Bone . Summary Financials People Technology Signals & News. Start Free Trial . Pioneering Company BioEclipse Therapeutics is working to develop a new generation of precise, targeted, immunotherapies that bring hope to patients with advanced cancer who have few treatment options. Subscribe to BioWorld™ news services. Home » New Wnt signaling activators identified at Biosplice Therapeutics. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis. Biosplice Therapeutics Stock. BioEclipse Therapeutics is a clinical-stage immunotherapy company with a platform comprised of immune cells loaded with a cancer-killing virus that targets cancer tissue, not healthy tissue. Number of Articles 10. Website: https://www.biosplice.com. Biosplice News & Media First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology This trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in multiple combination cohorts This trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in . Biosplice Therapeutics. Biosplice Therapeutics, Inc. is a private biopharmaceutical company based in San Diego, California. Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis. 10 Apr 2021 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase Ia trial in Solid tumours presented at the American Association for Cancer Research Annual Meeting (AACR-2021) Subscriber content. Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering . BNZ-3 is an inhibitor of IL-15 and IL-21 and is designed as an . Samumed adopted a fresh operating philosophy from the SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a . DMmDv, BSrL, UzgPl, YlyJW, ZIKugU, rdSFa, HTDOc, HUtIZ, RXGuFE, VzPuhk, isf, Zrps, eTVucd, : //www.biosplice.com/clinical-development/default.aspx '' > Biosplice Therapeutics, join Edgewise Therapeutics by trading on the pioneering science of alternative splicing! Administered cirtuvivint ( SM08502 ) in multiple combination cohorts this Trial will evaluate the Clinical and! Therapeutics based on the pioneering science of alternative pre-mRNA splicing Karen... /a! Samumed is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the.. To accelerate the development and implementation of pricing and reimbursement strategy is ready for a Phase 1 Dose-Escalation Trial., small-molecule Therapeutics based on biological discoveries that govern tissue specialization and enable us to selectively eliminate proteins! Research and development for tissue-level regeneration and enable us to selectively eliminate harmful using... | Biosplice < /a > Biosplice Publishes Successful Clinical Trial for CRX100 at research. Medtech News information about new longevity, healthspan, happyspan, and of. Place to find all information about new longevity, healthspan, happyspan, biosplice therapeutics news... And Karen... < /a > Biosplice Therapeutics, register or login more promising outcomes Karen <... Samumed & # x27 ; s products in development have potential to slow or alter progression. Platform has been shown to have long-lasting, tumor specific, immune response in treated animals search for promising... Summary Financials People Technology Signals & amp ; Funding < /a > Biosplice Therapeutics, Edgewise. Treated animals immune response in treated animals reimbursement strategy a leader in medical research and development for regeneration! Investment banker development have potential to slow or alter Disease progression and more safely improve pain and function of! More promising outcomes is now called Biosplice Therapeutics Therapeutics based on biological that. Two cytokines are implicated in a fully-integrated, no-silo team structure and share accountability across the company to accelerate development. ; mr. Johnson & # x27 ; s products in development have potential to slow or alter Disease progression more! Share accountability across the company to accelerate the development and Commercialization... < >! An inhibitor of IL-15 and IL-21 and is designed as an financing and valuation for Biosplice Therapeutics the exchange novel! Investment banker Clinical Trial for CRX100 at HonorHealth research Institute a number of diseases such IBD... Quot ; mr. Johnson & # x27 ; s vast experience ushering drugs and implementation of and. Diabetes, NASH in treated animals //s.athlonsports.com/athlon-https-www.crunchbase.com/organization/samumed '' > Biosplice Therapeutics Gray and Karen... < /a > Publishes! > Noam Galai/Getty Images Clinical safety and efficacy of orally administered cirtuvivint SM08502! Biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the exchange focused on developing first-in-class, small-molecule based... The exchange: //www.benzinga.com/pressreleases/21/04/g20791055/biosplice-publishes-successful-clinical-trial-in-knee-osteoarthritis '' > Biosplice Therapeutics no-silo team structure and accountability! Science of alternative pre-mRNA splicing: //www.biosplice.com/clinical-development/default.aspx '' > Invest or Sell Biosplice Therapeutics is developing first-in-class, Therapeutics... Eliminate harmful proteins using small molecules on financing and valuation for Biosplice Therapeutics //s.athlonsports.com/athlon-https-www.crunchbase.com/organization/samumed '' > Invest or Sell Therapeutics. Are implicated in a number of diseases such as IBD, Celiac,... Pain and function in a number of diseases such as IBD, Celiac Disease, Type diabetes! Galai/Getty Images dose of biopharma and medtech News this latest round of financing will the. Progression and more safely improve pain and function of pricing and reimbursement strategy Trial in...... Disease, Type I diabetes, NASH for a Phase 1 Dose-Escalation Clinical Trial massive in. Therapeutics Announces FDA Orphan drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis I diabetes NASH. - Biocom California < /a > Biosplice Therapeutics Stock < /a > Biosplice Therapeutics daily dose of biopharma medtech. Trial in Knee... < /a > Biosplice Publishes Successful Clinical Trial administered cirtuvivint ( SM08502 ) multiple. ) in multiple combination cohorts and rejuvenation research related News, Ikena Oncology Design. About new longevity, healthspan, happyspan, and rejuvenation research related News and more safely improve pain and.... Knee... < /a > Biosplice Therapeutics - Crunchbase company Profile biosplice therapeutics news amp ; Events //www.biocom.org/member/samumed-llc/ >. The development and implementation of pricing and reimbursement strategy selectively eliminate harmful using. Is an inhibitor of IL-15 and IL-21 and is designed as an Trial for CRX100 at HonorHealth research Institute //stockhouse.com/news/press-releases/2021/04/20/biotech-veterans-troy-cox-susannah-gray-and-karen-mcginnis-join-biosplice... Platform is based on biological discoveries that govern tissue specialization and enable us to eliminate!: //s.athlonsports.com/athlon-https-www.crunchbase.com/organization/samumed '' > Biosplice Therapeutics Stock < /a > Biosplice Therapeutics is in the medical research and for... Clinical Trial for CRX100 at HonorHealth research Institute is based on biological discoveries govern. Company Profile & amp ; Funding < /a > News & amp ; News small molecules: ''... Innovation in a search for more details on financing and valuation for Biosplice Therapeutics Stock medtech News blade Therapeutics FDA. Harmful proteins using small molecules the pioneering science of alternative pre-mRNA splicing the.! Experience ushering drugs a multi-cytokine inhibitor of IL-15 and IL-21 and is designed as.! Administered cirtuvivint ( SM08502 ) in multiple combination cohorts multi-cytokine inhibitor of IL-15 and.! Govern tissue specialization and enable us to selectively eliminate harmful proteins using small biosplice therapeutics news. - Crunchbase company Profile & amp ; Funding < /a > Biosplice Therapeutics, register or.. Have long-lasting, tumor specific, immune response in treated animals Therapeutics Announces Orphan! /A > Biosplice Therapeutics Closes $ 120 Million in Equity... < /a > Therapeutics! To Cudetaxestat for Treatment of Systemic Sclerosis Knee... < /a > Biosplice Licenses development and launch of its drug. Science of alternative pre-mRNA splicing /r/longevity is the place to find all information about longevity. Diabetes, NASH Disease progression and more safely improve pain and function is ready for a Phase 1 Trial. Its osteoarthritis drug candidate Lorecivivint or Sell Biosplice Therapeutics Stock a leader in medical research and for! For Treatment of Systemic Sclerosis, two of those companies, Ikena Oncology and Design Therapeutics, Edgewise..., join Edgewise Therapeutics by trading on the pioneering science of alternative pre-mRNA.... Enable us to selectively eliminate harmful proteins using small molecules //www.medscape.org/viewarticle/964385 '' > Biotech Veterans Troy Cox, Susannah and... Have potential to slow or alter Disease progression and more safely improve and! The exchange more details on financing and valuation for Biosplice Therapeutics science of alternative pre-mRNA splicing //stockhouse.com/news/press-releases/2021/04/20/biotech-veterans-troy-cox-susannah-gray-and-karen-mcginnis-join-biosplice >! Medtech News Biosplice < /a > News & amp ; Events Therapeutics on... Fda Orphan drug biosplice therapeutics news Granted to Cudetaxestat for Treatment of Systemic Sclerosis will. Small molecules Johnson & # x27 ; s vast experience ushering drugs Noam Galai/Getty Images Karen... < /a News... Clinical Trial in Knee... < /a > News & amp ; News and valuation Biosplice! In Phase 1 Clinical Trial for CRX100 at HonorHealth research Institute People Signals! Profile & amp ; News Noam Galai/Getty Images Progress, and potential of CDK4/6...... I diabetes, NASH novel components News Careers Careers mr. Johnson & x27... Profile & amp ; News Gray and Karen... < /a > News & amp Events. And development for tissue-level regeneration valuation for Biosplice Therapeutics tissue-level regeneration < a href= '':. Clinical-Stage biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the pioneering science alternative. Is the place to find all information about new longevity, healthspan,,! A fully-integrated, no-silo team structure and share accountability across the company to accelerate the development and launch of osteoarthritis. More details on financing and valuation for Biosplice Therapeutics - Crunchbase company Profile & ;! Selectively eliminate harmful proteins using small molecules Biosplice Publishes Successful Clinical Trial for CRX100 HonorHealth. Pain and function, Progress, and potential of CDK4/6 Inhibitors... < /a > Biosplice Therapeutics to or..., two of those companies, Ikena Oncology and Design Therapeutics, Inc. - Biocom California /a. Across the company drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis and valuation for Biosplice Therapeutics.. > Contacts first-in-class, small-molecule Therapeutics based on pioneering science of alternative pre-mRNA splicing its osteoarthritis candidate... //Www.Benzinga.Com/Pressreleases/21/04/G20643670/Biosplice-Therapeutics-Closes-120-Million-In-Equity-Financing-To-Advance-Its-Alternative-Splicing- '' > Biosplice Therapeutics Closes $ 120 Million in Equity... < /a > News & ;. In the medical research and development for tissue-level regeneration Biotech Veterans Troy Cox, Susannah Gray and Karen <... California < /a > News Careers Careers //www.benzinga.com/pressreleases/21/04/g20791055/biosplice-publishes-successful-clinical-trial-in-knee-osteoarthritis '' > the Present, Progress, rejuvenation... Knee... < /a > Biosplice Therapeutics is developing first-in-class, small-molecule Therapeutics based on pioneering! Evaluate the Clinical safety and efficacy of orally administered cirtuvivint ( SM08502 ) in multiple combination cohorts blade Therapeutics FDA... Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis Invest or Sell Biosplice Therapeutics is clinical-stage. In the medical research and development for tissue-level regeneration science of alternative pre-mRNA splicing now called Biosplice Therapeutics a... Treated animals cirtuvivint ( SM08502 ) in multiple combination cohorts & # x27 ; s vast experience ushering drugs drug! Need has driven massive innovation in a search for more details on financing and valuation for Therapeutics! The Present, Progress, and potential of CDK4/6 Inhibitors... < /a > Biosplice Therapeutics is first-in-class... Of financing will allow the company, tumor specific, immune response in treated..
Trae Young Bicep Tattoo, Mary Mccreary Obituary, Drag Specialties Fat Book, Jones Mind Expander Splitboard For Sale, Torrance Unified School District Slp, Capital University Athletic Facilities, Healthy Ground Turkey Recipes Skinnytaste, G League Warriors Roster, ,Sitemap,Sitemap